PharmaCom BioVet To File With FDA In Order To Perform Clinical Trials - Cancer Treatment For Canines

Main Category: Veterinary
Article Date: 12 Jun 2009 - 4:00 PDT

email to a friend   printer friendly   opinions  

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce that it is preparing a Form 21 CFR 511.1(b) for submission to the Federal Drug Administration (FDA). This initial form is one of several required if the Corporation decides to potentially run clinical trials on a histone deacetylase inhibitor for canines, which the Corporation is planning to develop. The histone deacetylase inhibitor is potentially for dogs suffering from an acute type of cancer, canine hemangiosarcoma.

"We are pleased to announce this filing with the FDA, because it is another positive step towards implementing our business plan and could possibly lead to future testing of cancer treatment medications for canines," stated Gary Berthold, President of PharmaCom BioVet, Inc.

Source
PharmaCom BioVet, Inc.

• Additional
• References
• Citations